Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3570 | Semi-structured telephone questionnaire Wiki | 0.45 |
| drug1952 | Injection into olfactory cleft Wiki | 0.45 |
| drug1190 | Detection of anti-COVID-19 antibody level Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020233 | Gait Disorders, Neurologic NIH | 0.45 |
| D009468 | Neuromuscular Diseases NIH | 0.45 |
| D061219 | Olfactory Nerve Injuries NIH | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002515 | Waddling gait HPO | 0.45 |
| HP:0001250 | Seizure HPO | 0.22 |
| HP:0001268 | Mental deterioration HPO | 0.12 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001297 | Stroke HPO | 0.11 |
| HP:0000458 | Anosmia HPO | 0.10 |
Navigate: Correlations HPO
There are 5 clinical trials
The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsThis randomized clinical trial will evaluate the benefit of platelet-rich plasma (PrP) in the treatment of olfactory dysfunction. PrP can be isolated from a patient's own blood and has been found in previous studies to have anti-inflammatory and pro-regenerative properties. It has been used across multiple specialties, such as Orthopedics, Facial Plastics, Dermatology, Neurology in injected form to treat a wide variety of tissues to encourage the body's inherent regenerative capacity. We have completed a pilot study here evaluating it's use in olfactory loss which demonstrated safety and also suggested efficacy. Therefore, we aim to assess the ability of PrP to improve olfactory function in patients with decreased sense of smell.
Description: Using Sniffin' Sticks olfactory testing pens to test smell
Measure: Smelling ability Time: 6 monthsThe objective of this research is to investigate the feasibility of delivering gait treatment using the Moterum iStride Solution™ to individuals with hemiparetic gait impairments using a telemedicine modality, the Moterum Digital Platform.
Description: The described delivery method includes using remote physical therapist treatment oversight and physical supervision of treatment activities by trained caregivers. Due to the inclusion criteria, patients already have some risk of falls and need for assistance while walking. The caregivers will record assistance levels provided during treatment. Any adverse events will be immediately reported and reviewed. The remote physical therapists will regularly review assistance levels to ensure the participant is requiring an appropriate level of assistance. The feasibility of safely delivering treatment will be assessed by two measures: (a) the daily safety rate, defined as the percentage of days an adverse event occurred out of the total number of treatment days, and (2) assistance required and adverse events experienced for each participant, compared to the group, and compared to our prior research.
Measure: Feasibility of safely implementing the treatment protocol Time: Determined at the end of the 12-session treatment period (approximately 4 weeks after beginning the treatment).Description: The achievability of this treatment delivery method will be assessed by measuring participant compliance to the protocol tasks. These tasks include scheduled treatment sessions, functional and psychosocial outcome measures, and sensor-based activities. Achievability will be defined as the percentage of completed protocol activities out of the total scheduled activities.
Measure: Achievability of telemedicine delivery protocol Time: Determined within one week after the final follow-up assessment (12-month follow-up) is completed. The 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.Description: To enroll patients via telemedicine, the eligibility criteria will be assessed with an additional video gait review performed by physical therapists. The feasibility of screening patients at a distance will be assessed by measuring screening performance, defined as the percentage of enrolled subjects who are removed from the study after later being deemed ineligible (for example, gait is not asymmetric or hemiparetic but appeared so on video, or patient cannot walk independently, etc.) out of all enrolled subjects.
Measure: Feasibility of screening criteria Time: Determined at the end of the 12-session treatment period (approximately 4 weeks after beginning the treatment).Description: Participant and caregiver feedback will be necessary to determine preferences and sentiments regarding the delivery method including technology management, training procedures, protocol activities, adequacy of caregiver and therapist support, device benefit, and overall satisfaction with procedures. Feedback will be gathered through a questionnaire using five-point Likert scales and open-ended questions. Questionnaires will be provided after completion of outcome measures at the final, 12-month follow-up assessment. Acceptability will be determined through percentage of positive responses out of the total questionnaire items.
Measure: Stakeholder Acceptability Time: Determined within one week after the final follow-up assessment (12-month follow-up) is completed. The 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.Patients with neurological or psychiatric symptoms or pre-existing disease will be sampled (blood for serum and DNA or saliva for DNA) at inclusion and at M6 (blood) and M12 (blood) depending on their pathology. Sampling will be done either at hospital if patient is on site for routine care or at home if no consultation is scheduled at hospital.
Description: dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients
Measure: dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients Time: 12 monthsDescription: Neurodegenerative markers (e.g., neurofilaments) associated with a neurological or psychiatric manifestation of Covid-19 infection
Measure: Serum neurofilaments Time: 12 monthsThis study aims to evaluate perceived clinical and psychosocial experiences of patients and their families during the Covid-19 pandemic. it is important to understand the implications of the pandemic for this population, particularly given its likely protracted course, and resultant limitations to daily activities and clinical care. This will help clinicians plan support and adaptations to the services they provide in the medium to long term.
Description: Evaluation of semi-structured questionnaires using thematic analysis
Measure: Qualitative evaluation of the perceived clinical and psychosocial impact of the Covid-19 pandemic in patients with neuromuscular and neurological disorders Time: 4 monthsDescription: Quantitative analysis of the proportion of questionnaire respondents reporting confirmed or suspected Covid-19 infection
Measure: Quantification of the proportion of patients with NMD who have had suspected or confirmed Covid-19 infection during the pandemic Time: 4 monthsDescription: Qualitative analysis describing the social environment of patients with NMDs
Measure: Qualitative evaluation of the social environment of patients with NMDs Time: 4 monthsDescription: Qualitative analysis describing the social activities of patients with NMDs
Measure: Qualitative evaluation of the social activities of patients with NMDs Time: 4 monthsDescription: Qualitative analysis describing the professional activities of patients with NMDs
Measure: Qualitative evaluation of the professional activities of patients with NMDs Time: 4 monthsDescription: Evaluation of semi-structured questionnaires using thematic analysis
Measure: Qualitative evaluation of the impact of the Covid-19 pandemic on families of patients with neuromuscular and neurological disorders Time: 4 monthsDescription: Evaluation of semi-structured questionnaires using thematic analysis
Measure: Qualitative evaluation of concerns regarding medical care from the perspective of patients with NMDs and their families during the Covid-19 pandemic Time: 4 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports